The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.
GLP-1s like the weight-loss drug Wegovy can be made by compounding pharmacies while they're in short supply. Drugmakers argue they no longer are.Ozempic and similar drugs for Type 2 diabetes and weight loss are in such high demand that the drugmakers have had a hard time keeping up. So compounding pharmacies stepped in to fill the gap, making their own versions of the drugs for more than two years.Novo Nordisk and Eli Lilly are moving to end compounding of their medicines for good.
"Everybody knows that… injections are going to come off the shortage list eventually and patients need to be prepared for that,"End the shortages, end compounding, small compounding pharmacies can't make copies of available brand name drugs more than four times a month. And bulk compounders, called outsourcing facilities, can't fill orders starting 60 days after a shortage ends.and a regular retail pharmacy about 15 miles apart in Durham, N.C.
"You'd think that would be a basic question because how do you know what the true market is if you haven't even asked how big it is?" Rosebush says. As a result, he argues, it's hard to know if Eli Lilly can supply the drugs for all the patients using name brand drugsCurrently, no reliable estimates of the compounding market for these drugs exist.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copiesThe Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make…
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: StudySemaglutide was associated with a 70% reduced risk when compared with insulin.
Read more »
Ozempic, Wegovy move closer to no longer being in shortage, FDA saysAll doses of the weight loss drugs are listed as 'available' by the FDA.
Read more »